The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents； (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions； (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents； (d) methods for the preparation of an atrasentan mandelate salt； and (e) atrasentan mandelate salts prepared by such method.
